Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study spotlights severe NAFLD in lean patients

Key clinical point: Nonalcoholic fatty liver disease (NAFLD) is uncommon in lean patients, but when it occurs, it is typically more severe than in overweight or obese patients.

Major finding: Advanced fibrosis occurred in 4.5% of lean patients with NAFLD, compared with 2.3% of obese patients.

Study details: A large population-based cohort study conducted in the general population in France.

Disclosures: The investigators disclosed relationships with Gilead, AbbVie, Echosens, and others.

Citation:

Serfaty L et al. The Liver Meeting 2019, Abstract 1188.